Weekly ReportAug 24–30, 2026
Sepsis, week 35 edition
We read 173 papers and selected 3.
Summary
This week’s sepsis literature showed a strong shift toward precision medicine, combining mechanism-based therapeutic targets, rapid pathogen diagnostics, and biologically informed risk stratification. Preclinical studies identified macrophage-centered pathways involving TG2–vimentin, PARP7–TBK1, NR1D1–IGF2BP2–V-ATPase, and CLEC-1 as potential targets for limiting inflammation or immune dysfunction. Diagnostic research advanced direct-from-blood pathogen detection and immune-cell phenotyping, while clinical cohorts developed models for acute kidney injury, pediatric shock, temperature-based risk, and mortality prediction. The main paradigm shift is the movement from nonspecific sepsis treatment toward host- and phenotype-directed care, although most innovations still require prospective impact validation.
Selected Articles
1. Transglutaminase 2 regulates vimentin-dependent proteostasis during macrophage activation.
This mechanistic study identified transglutaminase 2 (TG2) as a driver of sepsis-associated liver inflammation and multiorgan injury. TG2 cross-linked vimentin in macrophages, promoting cytoskeletal remodeling and sustained inflammatory signaling. Genetic deletion or pharmacological inhibition of TG2 improved survival and reduced inflammation in septic mice.
Impact: The study reveals a previously underrecognized link between cytoskeletal proteostasis and macrophage inflammation and demonstrates therapeutic benefit from TG2 inhibition in vivo. It offers a concrete mechanism-based strategy beyond nonspecific anti-inflammatory treatment.
Clinical Implications: TG2 inhibition could become a candidate treatment for sepsis-associated liver dysfunction and systemic inflammation, but human target engagement, safety, dosing, and timing must be established before translation.
Key Findings
- TG2 activity increased in macrophages and promoted liver inflammation in septic mice.
- TG2 cross-linked vimentin, while genetic or pharmacological TG2 inhibition improved survival and reduced multiorgan inflammation.
2. Rapid and robust diagnosis of bloodstream infections by single-cell analysis.
The STREAM platform enriched pathogens directly from whole blood and combined single-cell identification with antimicrobial susceptibility testing. It achieved 96.15% concordance for pathogen identification, high susceptibility agreement across 219 drug-dose combinations, and complete results within 6.75–17 hours, with detection limits as low as 0.1–1 CFU/ml.
Impact: The platform addresses the major diagnostic delay of conventional blood culture by offering rapid pathogen identification and susceptibility information directly from blood. If validated in routine suspected-sepsis populations, it could accelerate targeted treatment and reduce unnecessary broad-spectrum antibiotics.
Clinical Implications: STREAM may complement conventional blood culture and support earlier antimicrobial narrowing, particularly when prior antibiotics reduce culture yield. Prospective studies must establish effects on time to effective therapy, antibiotic exposure, resistance, and mortality.
Key Findings
- Pathogen identification showed 96.15% concordance with clinical laboratory results.
- Complete diagnostic results were available within 6.75–17 hours, with detection limits of 0.1–1 CFU/ml.
3. Macrophage PARP7 Alleviates Septic Cardiomyopathy by Interacting With TBK1 and Suppressing TBK1-Driven Inflammatory Response.
This study identified a macrophage-specific PARP7–TBK1 regulatory axis that limits inflammation in septic cardiomyopathy. PARP7 deficiency worsened cardiac injury, whereas macrophage-targeted AAV9-mediated PARP7 expression was cardioprotective in lipopolysaccharide and cecal ligation and puncture mouse models.
Impact: The work moves beyond descriptive inflammation by defining a cell-specific molecular brake and validating it with targeted gene delivery in two sepsis models. It provides a coherent therapeutic concept for septic cardiomyopathy, which currently lacks targeted treatments.
Clinical Implications: Enhancing macrophage PARP7 could eventually help prevent or treat septic cardiac dysfunction, but delivery specificity, immunogenicity, dosing, pathogen control, and safety require extensive validation before clinical translation.
Key Findings
- PARP7 deficiency exacerbated septic cardiomyopathy, while macrophage-specific PARP7 expression was cardioprotective.
- PARP7 interacted with TBK1 through ADP-ribosylation and reduced TBK1-driven inflammation in two murine sepsis models.